Tag: disease

Cosmos Health launches Oliv18™, a USDA and EU certified whole olive polyphenol supplement targeting cardiovascular and antioxidant categories.

DALLAS, June 05, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on June 1, 2026, the Compensation Committee of Taysha's Board of Directors granted four new employees, in the aggregate, restricted stock units (RSUs) representing 714,700 shares of the Company’s common stock and an option to purchase 468,600 shares of the Company's common stock in connection with their employment. The RSUs and stock option were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).

Breaking Through the "Blind Selection" Dilemma in Clinical Practice — TFC Taipei Fertility Center Introduces AI Scoring System to Help Infertile Couples End the...

HONG KONG, June 5, 2026 /PRNewswire/ -- UniTrust Global Limited | UTGL announced a donation of HK$650,000 to Prime Healthcare Medical Services Limited in...

Fangzhou showcased its “AI + Chronic Disease Services” digital solution developed in collaboration with Tencent Health.

European Commission approval expands the indication of lomitapide in the European Union (EU) to include children 5 years of age and older with HoFH, an ultra-rare genetic disorder affecting LDL-cholesterol levels

European Commission approval expands the indication of lomitapide in the European Union (EU) to include children 5 years of age and older with HoFH, an ultra-rare genetic disorder affecting LDL-cholesterol levels

The study showed that orelabrutinib was safe and well tolerated in participants with SLE.

SHANGHAI, June 4, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that its independently developed innovative...

The intravenous part of the Phase IIb clinical dose-finding trial PROCEED met its primary endpoint, with bocunebart demonstrating a statistically significant reduction in monthly...

LONDON, June 04, 2026 (GLOBE NEWSWIRE) -- London Specialist Dentists has announced the use of medical-grade Ozone Therapy as part of its advanced approach to periodontal treatment, dental implant care, and minimally invasive gum therapy.

The article outlines how deep cleaning and routine care address gum disease and protect long-term oral health.LAGRANGE, Ga., June 4, 2026 /PRNewswire/ -- Why...

Ethics Committee Approval Received for Pivotal Study Intended to Support U.S. FDA Class II Submission for QuickScan™ Strep AVANCOUVER, BC, June 4, 2026 /CNW/...